A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Chinese Patients with Advanced Non-small Cell Lung Cancer (NSCLC) patients with EGFR or HER2 Mutations
| Title | A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Chinese Patients with Advanced Non-small Cell Lung Cancer (NSCLC) patients with EGFR or HER2 Mutations |
|---|---|
| Description | This study includes dose escalation and dose expansion parts. Dose expansion was triggered at dose levels that anti-tumor efficacy was observed in EGFR Exon20ins or HER2 Exon20ins patients. The primary objective is to evaluate safety and tolerability and define MTD and RP2D. |
| Organism | Homo sapiens |
| Data Type | Other Type of Metabolome Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA010938 |
| Release Date | 2022-08-03 |
| Submitter | mengzhao wang (mengzhaowang@sina.com) |
| Organization | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College |
| Submission Date | 2022-08-02 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX001474-01 | PK data from WK2 study | 1 | Other Type of Metabolome Data | 435.7 KB | rar | 0 | Controlled |